Pay in 4 interest-free payments of $6.07 Learn more
Ships within 48 hours Β· Estimated delivery Aug 16 - Aug 21
Molecular targets for ADCs in prostate cancer The successful development of radioligand therapies for prostate cancer, such as lutetium vipivotide tetraxetan (177Lu-PSMA-617), as well as advances in the understanding of histological features and expression of prostate cancer antigens reinvigorated the landscape of ADC development in prostate cancer 66
The abdomen, thighs, and upper arms are recommended sites
The topology of the conformational epitope indicates that binding of the nanobody prevents the conformational change to the postfusion form necessary for membrane fusion, which in turn would explain the neutralizing activity
Rotate injection sites to prevent tissue damage and maintain optimal absorption
US$ 25.55
US$ 22.54
US$ 22.32
US$ 24.06
US$ 29.48
